Q1 2026 Management View “Overall, Q1 reflected continued progress on transforming Harvard Bioscience from a traditional tool provider into a leading supplier of the emerging translational science ...

CBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available ...

Shift Bioscience is building a cell simulation platform that combines generative AI with its highly accurate, high-throughput biological aging clock, to predict which sets of genes are most likely to ...

Q2 FY26 earnings call highlights: raised revenue guide, AI-enabled drug discovery, AWS partnership, margin and EBITDA outlook.

Niagen Bioscience (NAGE) is back on investor radars after reporting first quarter 2026 earnings, with sales of US$31.47 million and net income of US$6.32 million from continuing operations. See our ...

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its clonal genes portfolio with the early access launch of Complex Genes.

Tru Niagen is expanding its patented nicotinamide riboside, known as Niagen, into skincare and beauty supplements. Driven by consumer demand, Niagen Bioscience’s leadership in N ...

Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in NAD+ (nicotinamide adenine dinucleotide) science and ...

Artisan Partners, an investment management company, released its first-quarter 2026 investor letter for the “Artisan Mid Cap ...

Shift Bioscience, a biotech company using an AI powered virtual cell to fight age-related diseases, today announced the establishment of a new North American team and facilities to advance development ...

Margaret R. McLean delivered this address to the Keck Graduate Institute Convocation in September 2010. She is associate director of the Markkula Center for Applied Ethics and Director of Bioethics.

Humans wiped out the bluebuck in Africa around 200 years ago. Bringing it back is both ethically and technologically ...